Skip to main content

Table 1 Baseline characteristics of HIV-Infected, HCV-Infected, and HIV/HCV-coinfected patients (n = 59)

From: A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection

Variable

Strata A (N = 15)

Strata B (N = 15)

Strata C (N = 14)

Strata D (N = 15)

P

Demographics

     

 Sex, N (%)

    

1.00

  Female

4 (27)

4 (27)

4 (29)

4 (27)

 

  Male

11 (73)

11 (73)

10 (71)

11 (73)

 

 Age, years

53 (51–56)

54 (51–56)

54 (52–56)

53 (42–66)

0.95

Race/Ethnicity, N (%)

    

0.21

  African American/non-Hispanic

11 (73)

12 (80)

9 (64)

13 (87)

 

  Caucasian/non-Hispanic

4 (27)

2 (13)

4 (29)

0

 

  Caucasian/Hispanic

0

1 (7)

1 (7)

2 (13)

 

 Laboratory values

     

 ALT (U/L)

18(11–82)

43 (19–78)

23(14–88)

22 (10–77)

0.0009

 AST (U/L)

19 (14–52)

37 (23–84)

30 (18–83)

24 (18–55)

0.0002

 Albumin (g/dL)

4.2 (3.8-5.1)

4.0 (3.4-4.7)

4.3 (2.7-4.7)

4.2 (3.8-5.0)

0.29

 Total cholesterol (mg/dL)

168 (118–253)

155 (88–200)

147.5 (98–207)

171 (124–220)

0.24

 hs-CRP (mg/L)

4.0 (0.5-11.3)

1.2 (0.2-36.9)

0.7 (0.2-27.2)

3.5 (0.2-65.3)

0.08

 D-dimer (μg/mL)

0.34 (0.19-0.98)

0.34 (0.21-2.25)

0.22 (0.19-2.07)

0.35 (0.19-1.49)

0.41

Risk factors, N (%)

     

 Sexual preference

    

0.01

  MSM

6 (40)

1 (7)

1 (7)

1 (7)

 

  Heterosexual

7 (47)

14 (93)

11 (79)

14 (93)

 

  Bisexual

2 (13)

0

2 (14)

0

 

Alcohol use, N (%)

    

0.32

  > once a week

4 (27)

1 (7)

2 (14)

0

 

  < weekly, but > monthly

2 (13)

1 (7)

2 (14)

1 (7)

 

  Monthly or less

9 (60)

13 (86)

10 (72)

14 (93)

 

Injection drug use ever, N (%)

    

<0.0001

  Yes

1 (7)

9 (60)

13 (93)

9 (60)

 

  No

14 (93)

6 (40)

1 (7)

6 (40)

 

TE-derived fibrosis score*

4.4 (3.0-11.6)

7.9 (4.7-29.9)

7.6 (3.2-22.3)

5.9 (3.0-9.1)

0.001

Current CD4 count (cells/μL)

495 (296–956)

-

457 (299–651)

668 (295–1117)

0.01

Nadir CD4 count (cells/μL)

168 (22–415)

-

225 (13–428)

302 (124–918)

0.08

Duration of ARVs (years)

9 (1–25)

-

11(3–15)

6 (0–20)

0.59

Estimated duration of HIV (years)

12 (2–25)

-

17 (5–31)

19 (1–28)

0.69

Estimated duration of HCV (years)

-

24 (15–40)

30 (12–38)

26 (3–37)

0.23

HCV viral load (IU/mL)

-

974,248 (1,622-4,604,960)

706,476 (17,145-20,000,000)

-

0.95

  1. Values are expressed as median (range) unless otherwise noted. *TE-derived fibrosis scores correlate with Metavir fibrosis staging system as follows: <7.1 = stage 0–1, 7.1-9.4 = stage 2, 9.5-12.4 = stage 3, and ≥ 12.5 = stage 4.
  2. Strata: A = HIV monoinfection, B = HCV monoinfection, C = HIV/HCV coinfection with CHC, D = HIV/HCV coinfection with cleared HCV.
  3. Abbreviations: ARV, antiretroviral; hsCRP, high sensitivity C-reactive protein; MSM, men who have sex with men; TE, transient elastography.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us